On Monday, Shares of Apple Inc. (NASDAQ:AAPL), lost -1.98% to $112.44.
Apple, declared it has sold more than 13 million new iPhone® 6s and iPhone 6s Plus models, a new record, just three days after launch. iPhone 6s and iPhone 6s Plus will be available in more than 40 additional countries starting October 9 counting Italy, Mexico, Russia, Spain and Taiwan. The new iPhones will be available in over 130 countries by the end of the year.
iPhone 6s and iPhone 6s Plus bring a powerful new dimension to iPhone’s revolutionary Multi-Touch™ interface with 3D Touch, which senses how deeply you press the display, letting you do essential things more quickly and simply. The new iPhones introduce Live Photos, which bring still images to life, transforming instants frozen in time into unforgettable living memories. Live Photos, 3D Touch, 12-megapixel iSight® camera, 5-megapixel FaceTime® HD camera with Retina® Flash and more are powered by the Apple-designed A9 chip, the most advanced chip ever in a smartphone, delivering faster performance and great battery life. iPhone 6s and iPhone 6s Plus are designed with the strongest glass on any smartphone and 7000 series aluminum, the same alloy used in the aerospace industry, in gorgeous metallic finishes that now comprise rose gold.
iOS 9, the world’s most advanced mobile operating system, brings more intelligence to iPhone with proactive assistance, powerful search and improved Siri features, all while protecting users’ privacy. Built-in apps become more powerful with a redesigned Notes app, detailed transit information in Maps*, and an all-new News app for the best news reading experience on any mobile device. The foundation of iOS is even stronger with software updates that require less space to install and advanced security features to further protect your devices.
Apple Inc. (Apple) designs, manufactures and markets mobile communication and media devices, personal computers, and portable digital music players, and a variety of related software, services, peripherals, networking solutions, and third-party digital content and applications.
Shares of Mylan NV (NASDAQ:MYL), declined -6.31% to $40.86, during its last trading session.
Mylan, declared the U.S. launch of Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg and 9 mg, the generic version of Janssen’s Invega®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of schizophrenia in adults and adolescents (12 – 17 years of age) in addition to schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants in adults.
Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg and 9 mg, had U.S. sales of about $606.2 million for the 12 months ending June 30, 2015, according to IMS Health.
Presently, Mylan has 260 ANDAs pending FDA approval representing $98.7 billion in annual brand sales, according to IMS Health. Fifty of these pending ANDAs are potential first-to-file opportunities, representing $33.4 billion in annual brand sales, for the 12 months ending December 31, 2014, according to IMS Health.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty.
Shares of Horizon Pharma PLC (NASDAQ:HZNP), declined -20.96% to $18.00, during its last trading session.
Horizon Pharma, commented on Institutional Shareholder Services’ (“ISS”) recommendation in support of Horizon Pharma’s efforts to call two related special meetings of Depomed shareholders to remove and replace all of the current Depomed, Inc. (“Depomed”) directors and to repeal a series of recent amendments to Depomed’s bylaws.
In a published report, ISS unequivocally recommended that shareholders of Depomed PROVIDE CONSENT FOR Horizon Pharma’s solicitation for the calling of the special meetings, by submitting their WHITE and BLUE proxy cards to Horizon Pharma’s proxy solicitor, MacKenzie Partners, Inc. In reaching its recommendation, ISS spoke with representatives of Horizon Pharma and Depomed and thoroughly analyzed both companies’ respective filings and other publicly available materials.
ISS concluded that:
- “Given that the poison pill and unilateral bylaw amendments adopted by the Depomed board materially impact shareholder rights, shareholders should provide consent FOR the special meetings.”
- “The new bylaws adopted by the board do not appear to strike an appropriate balance between the board’s need for more time to evaluate hostile bids and shareholders’ ability to voice their views on planned and governance decisions.”
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs.
Finally, Schlumberger Limited, (NYSE:SLB), ended its last trade with -4.84% loss, and closed at $69.37.
Schlumberger Limited has received an “A+” credit rating from analysts at Morningstar. The firm’s “A+” rating suggests that the company is a low default risk. They also gave their stock a four star rating.
The business also recently revealed a quarterly dividend, which will be paid on Friday, October 9th. Stockholders of record on Wednesday, September 2nd will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.74%. The ex-dividend date of this dividend is Monday, August 31st.
Schlumberger N.V. is a supplier of technology, integrated project management and information solutions to the international oil and gas exploration and production industry.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
